CN105456428A - 一种抑制肿瘤细胞再生长的中药配方及其制备方法 - Google Patents
一种抑制肿瘤细胞再生长的中药配方及其制备方法 Download PDFInfo
- Publication number
- CN105456428A CN105456428A CN201511022537.9A CN201511022537A CN105456428A CN 105456428 A CN105456428 A CN 105456428A CN 201511022537 A CN201511022537 A CN 201511022537A CN 105456428 A CN105456428 A CN 105456428A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine formula
- traditional chinese
- medicinal liquid
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims description 8
- 230000002401 inhibitory effect Effects 0.000 title abstract description 3
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 241000190633 Cordyceps Species 0.000 claims description 22
- 241000222336 Ganoderma Species 0.000 claims description 19
- 239000009636 Huang Qi Substances 0.000 claims description 17
- 241000522620 Scorpio Species 0.000 claims description 15
- 239000009490 scorpio Substances 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 8
- 241000269417 Bufo Species 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000004575 stone Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 41
- 230000000694 effects Effects 0.000 abstract description 37
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 5
- 235000006533 astragalus Nutrition 0.000 abstract description 5
- 206010006187 Breast cancer Diseases 0.000 abstract description 4
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 abstract description 4
- 201000002313 intestinal cancer Diseases 0.000 abstract description 4
- 241001061264 Astragalus Species 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 210000004233 talus Anatomy 0.000 abstract description 3
- 240000008397 Ganoderma lucidum Species 0.000 abstract description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract description 2
- 241001248610 Ophiocordyceps sinensis Species 0.000 abstract description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 2
- 206010017758 gastric cancer Diseases 0.000 abstract description 2
- 230000003340 mental effect Effects 0.000 abstract description 2
- 201000011549 stomach cancer Diseases 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 2
- 241000269420 Bufonidae Species 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 240000005373 Panax quinquefolius Species 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 241000915604 Scutellaria barbata Species 0.000 abstract 1
- 241001149649 Taxus wallichiana var. chinensis Species 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
- 210000002683 foot Anatomy 0.000 description 55
- 201000011510 cancer Diseases 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 14
- 238000011282 treatment Methods 0.000 description 12
- 230000001093 anti-cancer Effects 0.000 description 11
- 229960001592 paclitaxel Drugs 0.000 description 11
- 208000008454 Hyperhidrosis Diseases 0.000 description 10
- 229930012538 Paclitaxel Natural products 0.000 description 10
- 208000013460 sweaty Diseases 0.000 description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 10
- 206010067197 Tinea manuum Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000007654 immersion Methods 0.000 description 9
- 231100000614 poison Toxicity 0.000 description 9
- 201000004647 tinea pedis Diseases 0.000 description 9
- 241000905957 Channa melasoma Species 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000036737 immune function Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000628997 Flos Species 0.000 description 6
- 230000000474 nursing effect Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 241000219784 Sophora Species 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 3
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- QEEBRPGZBVVINN-UHFFFAOYSA-N Desacetyl-bufotalin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C1(O)CCC2C=1C=CC(=O)OC=1 QEEBRPGZBVVINN-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- BJBUTJQYZDYRMJ-UHFFFAOYSA-N Kaempferol 3,7-dimethyl ether Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C=C1 BJBUTJQYZDYRMJ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 241001116500 Taxus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- QEEBRPGZBVVINN-BMPKRDENSA-N bufalin Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)CC[C@@]32C)C=CC(=O)OC=1 QEEBRPGZBVVINN-BMPKRDENSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000020995 raw meat Nutrition 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- HDTHCLKLBSPBIS-JBXNKDOXSA-N (2s)-2-[[8-[[(3s,5r,8r,9s,10s,13r,14s,16s,17r)-16-acetyloxy-14-hydroxy-10,13-dimethyl-17-(6-oxopyran-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-8-oxooctanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@@H](C[C@H]5CC[C@H]4[C@@]3(O)C[C@@H]2OC(=O)C)OC(=O)CCCCCCC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C=CC(=O)OC=1 HDTHCLKLBSPBIS-JBXNKDOXSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 235000006793 Artemisia stelleriana Nutrition 0.000 description 1
- 244000252230 Artemisia stelleriana Species 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- HAJGVUYNXHQLER-UHFFFAOYSA-N Bufadienolide Natural products O1C(=O)C=CC(C2C3C(C4C(C5CCCCC5CC4)CC3)CC2)=C1 HAJGVUYNXHQLER-UHFFFAOYSA-N 0.000 description 1
- HDTHCLKLBSPBIS-UHFFFAOYSA-N Bufotoxin Natural products CC(=O)OC1CC2(O)C3CCC4CC(OC(=O)CCCCCCC(=O)NC(CCCN=C(N)N)C(O)=O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 HDTHCLKLBSPBIS-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010023798 Charybdotoxin Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000221751 Claviceps purpurea Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000422920 Cordyceps gunnii Species 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000002655 Foot Dermatoses Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000130660 Hepialidae Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 240000005308 Juniperus chinensis Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000319345 Metacordyceps liangshanensis Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000000475 acetylene derivatives Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000000919 anti-host Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- YBPMPRDOWHIVNA-XTBIJCDISA-N bufadienolide Chemical compound C=1([C@H]2CC[C@@H]3[C@H]4[C@@H]([C@]5(CCCCC5CC4)C)CC[C@@]32C)C=CC(=O)OC=1 YBPMPRDOWHIVNA-XTBIJCDISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000006413 coastal sagewort Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002795 scorpion venom Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 125000002456 taxol group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种抑制肿瘤细胞再生长的中药配方，它是由以下重量百分比份的原料制成：灵芝、红豆杉、蟾蜍、冬虫夏草、西洋参、全蝎、黄芪、半枝莲、百花蛇舌草。本发明通过熬制提取各味中药中的药性精华，并通过组合各味中药，各原料之间协同增效，可以增强血液循环，温暖气血，改善精神状况，同时可治疗该药主治各种癌症.根据服法结果，已经治愈了肠癌，肝癌，子宫癌，胃癌等，除乳癌效果差点外，其他癌症都有良好效果，特别是肠癌，能起到异常效果。
Description
技术领域
本发明涉及一种抑制肿瘤细胞再生长的中药配方及其制备方法。
背景技术
转移是肿瘤恶性生物学行为的特征性表现，是导致临床治疗失败、影响肿瘤患者长期生存的主要因素。如何阻断肿瘤的浸润转移是提高肿瘤治疗水平及治愈肿瘤的关键。近年来研究表明，新生血管生成是肿瘤生长和转移的必要条件之一。断绝或减少肿瘤血管供应，抑制肿瘤血管生成是控制肿瘤生长和转移的重要途径，寻找新的高效低毒血管生成抑制剂已成为当前抗肿瘤转移药物研究的热点课题。
发明内容
为了克服现有技术的不足，本发明提供一种抑制肿瘤细胞再生长的中药配方及其制备方法。
本发明解决其技术问题所采用的技术方案是：
一种抑制肿瘤细胞再生长的中药配方，它是由以下重量百分比份的原料制成：灵芝10％-15％、红豆杉30％-35％、蟾蜍20％-30％、冬虫夏草5％-10％、西洋参8％-15％、全蝎20％-25％、黄芪15％-20％、半枝莲5％-8％、百花蛇舌草5％-15％。
优选的是，它是由以下重量份的原料制成：灵芝10％-12％、红豆杉30％-33％、蟾蜍25％-28％、冬虫夏草6％-8％、西洋参10％-12％、全蝎22％-23％、黄芪16％-18％、半枝莲6％-8％、百花蛇舌草10％-15％。
一种抑制肿瘤细胞再生长的中药配方的制备方法，包括以下步骤：
(1)将各组分原料分别进行筛选去除杂质，按所述配比称取，备用；
(2)将灵芝、红豆杉、冬虫夏草、西洋参、黄芪、半枝莲、百花蛇舌草混合，再加入10-15倍分量的矿泉水，浸泡5小时；
(3)将步骤2中混合物和水中加入全蝎、蟾蜍，放在石锅中煎熬3-5小时，煎熬的过程中不断的搅拌，待水量剩余一半时，重新加入水，大火煎熬1小时，取30％药液；再次重新加入水，继续大火煎熬3-5小时，取60％药液；
(4)将步骤3中剩余的药渣药液继续采用小火煎熬，待药液浓厚成粘稠状，停止加热，分离药渣和药液；
(5)将步骤4中的药渣，碾碎，备用；
(6)将步骤4和步骤3中所得的药液按照3:2:1的比例，调兑，即可得成品药液；
优选的是，步骤5和步骤6中所得药渣和药液需同时使用。
配方中的各组分的作用如下：
灵芝甘、平。益精气，养心安神，止咳平喘，滋养强壮，补虚抗癌。多孔菌科植物紫芝或赤芝的子实体。[别名]瑞草、菌灵芝。子实体含灵芝三萜、灵芝多糖、蛋白质、有机锗、微量元素硒、灵芝纤维素、多种氨基酸等成分，有提高免疫功能，抑制癌细胞，治白血病的作用。
灵芝是最佳的免疫功能调节和激活剂，它可显著提高机体的免疫功能，增强患者自身的抗癌能力。能保护癌症患者体内正常细胞的DNA不再氧化、被癌化，防止癌细胞的再生。
灵芝可以通过促进白细胞介素-2的生成，通过促进单核巨噬细胞的吞噬功能、通过提升人体的造血能力尤其是白细胞的指标水平，以及通过其中某些有效成分对癌细胞的抑制作用，成为抗肿瘤、防癌以及癌症辅助治疗的优选药物。灵芝能增强癌症患者体内免疫系统，包括胸腺、脾腺、骨髓造血机能、红血球、白血球等整个免疫系统的功能。增加免疫细胞，尤其是专门对付癌细胞的Tc杀手细胞、自然杀手细胞(N.K细胞)和巨噬细胞的质与量。能激发干扰素、肿瘤坏死因子、白介素等细胞激素的自体生成而达杀灭癌细胞的目的。
灵芝能使癌症患者机体较放松，易于睡眠、易于饮食。可增加癌症患者疼痛的耐受性，具有解压、镇静、镇痛的作用。灵芝对人体没有任何毒副作用。这种无毒性的免疫活化剂的优点，恰恰是许多肿瘤化疗药物和其它免疫促进剂都不具有的。总之，灵芝有助于人体血液的清澈及正常细胞组织的运作，创造出癌栓不易形成、癌细胞不适生存的空间让人体自体治癌。
红豆衫
红豆衫又称紫杉，属国家一级保护的珍稀常绿乔木，枝、叶、皮、根可提取昂贵抗癌药物——紫杉醇。从红豆杉的树皮和树叶中提炼出来的紫杉醇对多种晚期癌症疗效突出，被称为“治疗癌症的最后一道防线”。高纯度紫杉醇价格昂贵，每公斤200红豆杉万元人民币左右。但是红豆杉生长缓慢，天然更新能力差，人工种植10亩仅能提炼1公斤1％纯度的紫杉醇。由于红豆杉的提取物(TAXOLPACLITAXEL)紫杉醇具有独特的抗癌机理，美国国立肿瘤研究所所长BRODER博士称紫杉醇是继阿霉素、顺铂以后，十五年来被认为是对多种癌症疗效较好、副作用小的新型抗癌药物。红豆杉中含有的紫杉醇，具有独特的抗癌机制和较高的抗癌活性，能阻止癌细胞的繁殖、抑制肿瘤细胞的迁移，被公认是当今天然药物领域中最重要的抗癌活性物质。据专家介绍，紫杉醇不溶于水或酒精之类溶解物，它的淬取技术非常复杂、加工程序十分严密，直接使用红豆杉树皮或根茎是不能治病的。目前，全球每年大约死于癌症的病人在630万人左右，仅美国、欧洲、日本每年就在400万人左右。治疗这些病人每年大约消耗1500∽2500千克紫杉醇。一位研究紫杉醇的美国专家说，即使将世界上现有的红豆杉全部砍伐，所提取的紫杉醇也只能挽救12.50万名癌症患者的生命。
蟾蜍
味腥、温，有毒。归心经，具有解毒、止痛、开窍等功效。中国民间中医医药研究开发协会编《癌症独特秘方》中载：蟾皮性味腥、凉、微毒，功能解毒、利水、消胀、主治各种肿癌。1999年经上海交大量子医学检测，特别对癌症、肝硬化、疼痛诸症的治疗有效含量成份超8千量价上(凡有8千量价以上有免疫功能成份)。华夏出版社《中华医药全典》中载：蟾衣毒较轻，主要用于疮疡肿毒及小儿疳积，现代常用治肿瘤。远方出版社《中草药大全》中介绍，蟾衣可治癌、白血病、淋巴瘤等。
据民间应用调查，蟾衣有清热、解毒、消肿止痛、镇静、利尿、壮阳、抗感冒病毒的功效，并对肝腹水、癌症有显效，对乙肝大三阳、小三阳可转阴，还能迅速有效地增强体质和提高免疫功能，促进人本代谢自然平衡。服法请遵医嘱。
蟾衣是蟾酥浆液的表皮包衣，孙思邈称：“蟾蜕(衣)除恶肿，神也”。李时珍《本草纲目》称：“蟾衣乃其蓄足五脏六腑之精气，吸纳天地阴阳之华宝，如若获之一，一切恶疾，未有不愈”。中医认为蟾衣具有解毒消肿、止痛、辟秽浊之功效，广泛用于疮痈肿毒、咽喉肿痛等的治疗。现代研究认为：蟾衣主主含蟾蜍二烯醇化合物，包括蟾毒配质及蟾蜍毒素，具有强心、升压、抗炎作用，蟾毒配质还有较强的麻醉作用。最近科研人员发现蟾衣还有抗肿瘤、抗病毒等多种神奇功能，可用于治疗多种恶性肿瘤、肝炎、带状疱疹、肝腹水、肾病、乳腺增生、子宫肌瘤等疑难杂症。
冬虫夏草
冬虫夏草，是麦角菌科真菌冬虫夏草寄生在蝙蝠蛾科昆虫幼虫上的子座及幼虫尸体的复合体，种类较多，包括有冬虫夏草、亚香棒虫草、凉山虫草、新疆虫草、分枝虫草、藿克虫草、蛹虫草、武夷山虫草、龙洞虫草、张家界虫草、大塔顶虫草等四百多种。冬虫夏草是一种传统的名贵滋补中药材，有调节免疫系统功能、抗肿瘤、抗疲劳等多种功效。冬虫夏草的主要成分包括虫草酸、虫草素、氨基酸、甾醇、甘露醇、生物碱、维生素B1、B2、多糖及矿物质等。具有抗癌、滋补、免疫调节、抗菌、镇静催眠等功效。传统医学《本草从新》记载：“味甘性温，秘精益气，专补命门。”现代医学研究证实，其成分含脂肪、精蛋白、精纤维、虫草酸、冬虫草素和维生素B12等。
冬虫夏草有很好的药用价值，常见的有用于抗肿瘤，提高免疫，提高细胞能力，改善心脏功能，调节呼吸系统，肾脏功能，提高造血功能，调节血脂，调节性功能等。其中抗肿瘤效果和提高免疫功能同时用于临床恶性肿瘤的治疗能取得很好的效果。
冬虫夏草提取物在体外具有明确的抑制、杀伤肿瘤细胞的作用。冬虫夏草中含有虫草素，是其发挥抗肿瘤作用的主要成分。临床上使用虫草素多为辅助治疗恶性肿瘤，症状得到改善的在91.7％以上；主要用于鼻癌、咽癌，肺癌，白血病，脑癌以及其他恶性肿瘤的患者。很多抗肿瘤中成药也是以冬虫夏草为主要原料制成的，如清肺散结丸，可在提高免疫功能的同时抑制癌细胞，在治疗肺癌上有针对性强，见效快等特点，无副作用，安全有效。
西洋参
甘、微苦，寒。归肺、心、肾、脾经。补气养阴，清火生津。主要成分为人参皂甙、挥发油、树脂等。西洋参茎叶中尚含人参皂甙Rh1，含量为0。001％左右。
[功效]益气生津，养阴清热。
[应用]肿瘤病人症见气阴两虚所致的心烦口渴、久咳干咳、痰少咯血、气短乏力、咽喉干燥、声音嘶哑、午后潮热、手足心热等，均可使用。
人参皂甙Rh2对小鼠肉瘤S-180有较强的抗癌作用，用于鼻咽癌放疗反应，以西洋参3g，水煎服，每日1剂，于放射治疗前二星期开始，直至放疗完毕。对防治因放疗所引起的咽干、胃口不佳等症状有较好效果。观察20多例，提示比人参效果为佳。
日本藤本康雄等从西洋参分离现具有抗肿瘤作用的乙炔衍生物。将西洋参粉碎后，用乙酸乙酯提取，浓缩，将所得到的粗提取物经Hp-20(洗脱液：H2O-Me-OH)硅胶层析，再以HPLC精制。结果，分离出对培养的肿瘤细胞的生长具有强抑制作用的4种已知乙炔类和2种新乙炔类成分。
西洋参总甙与人参皂甙均有显著抗疲劳、抗利尿、抗缺氧能力，但作用强度有别。抗利尿作用人参明显高于西洋参，强壮作用西洋参也较人参弱。
全蝎
全蝎，又名钳蝎、全虫、蝎子，味辛，性平；有毒。归肝经。全蝎的主要药用成分为蝎毒素，包括神经毒素和细胞毒素，具有熄风镇痉、消炎攻毒、通络止痛的功效。蝎毒对神经系统、消化系统、心脑血管系统、癌症、皮肤病、等多种疾病，以及对人类危害极大的各种病毒均有预防和抑制作用。
临床试验数据：全蝎提取物0.2ml，隔大皮下给药连续5天后，在用药第11天和停药8天时，对细胞肉瘤(SRS)实体瘤的抑制率为38.8％和55.5％；对MA一737乳腺癌，每天给药共12次后，抑制率为51.8％，停药8天时为30.4％。对SRS腹水型带瘤子鼠的生存率较对照组延长12.5％-20.7％。对LA一795肺腺癌带瘤小鼠生存时间延长29.2％。
全蝎跟多种药材配伍可用于多种恶性肿瘤的治疗，如全蝎与人参、生黄芪、白术、鸡内金、栝蒌、清半夏、厚朴、枳壳、郁金、丹参、蜈蚣等配伍(参丹散结胶囊组方)可用于治疗乳腺癌、肺癌、胃肠癌等，改善肿瘤(脾虚痰瘀)患者胸痛、面色晄白纳谷少馨、少气懒言、气短等症状。
黄芪
甘，微温。归脾、肺经。补脾肺气，升阳举陷，益卫固表，利尿，托毒生肌。黄芪为豆科植物蒙古黄芪膜荚黄芪的干燥根。含氨基酸、粘液质、糖类、苦味素、胆碱甜菜碱叶酸、熊竹素，β-谷甾醇(、黄芪多糖等。凡癌症患者因脾肺气虚所致面色白光白，倦怠无力，纳少便溏，吐血便血，咳喘气短，痰多稀白，少气懒言，乏力自汗，心悸失眠，气虚发热，浮肿尿少等均可用之。《本草害利》云："黄芪极滞胃口，胸胃不宽，肠胃有积滞者勿用，，，，黄芪能增强网状内皮系统的吞噬功能，如与灵芝、党参合用，此作用更为明显。黄芪对干扰素系统有促进作用。黄芪及黄芪多糖以使动物脾内浆细胞增生，促进抗体合成，对体液免疫有促进作用。
黄芪水煎液不仅在外可促进小鼠NK(天然杀伤)细胞的活性，而且在小鼠口服100％水煎剂(每日0。5ml)，连续7天后，脾脏中的NK细胞比未用黄芪组高1。84-2。04倍(P<0。05)。试验还表明黄芪诱生干扰素对NK细胞活性的促进作用，较L929-B细胞诱生干扰素作用大4-6倍。小鼠脾细胞事先用不同浓度黄芪水煎液在37℃处理2小时，则对小鼠艾氏腹水癌细胞(EAC)的得天独厚细胞毒活性明显增加。
黄芪提取物(Fs)在体外抗宿主反应试验中，显示对癌患者淋巴细胞功能有完全性免疫恢复作用。在体内动物实验模型中，可显示出全部逆转因环磷酰胺而造成的免疫抑制现象。提示Fs可能是一种很有希望的生物反应调节剂。
据南斯拉夫学者在第37届药用植物研究年会论文报告中指出：黄芪复方(黄氏30克，芍药20克，甘草10克，姜2克，枣3克，麦芽糖20克)对癌前病变胃溃疡有极好疗效。临床上对40名经放射学诊断为胃溃疡的病人，年龄20-60岁，病程1年-20年，口服煎剂一个月后，治愈率为55％，六个月后达90％。对45只大鼠进行实验，也表明了黄芪复方本发明所用到的原料药材均可从普通药店购买得到，其规格符合国家医药标准。
本发明的有益效果是：本发明通过熬制提取各味中药中的药性精华，并通过组合各味中药，各原料之间协同增效，可以增强血液循环，温暖气血，改善精神状况，同时可治疗该药主治各种癌症.根据服法结果，已经治愈了肠癌，肝癌，子宫癌，胃癌等，除乳癌效果差点外，其他癌症都有良好效果，特别是肠癌，能起到异常效果。
具体实施方式
实施例1：一种足部浸泡用中药护理液，它是由以下重量份的原料制成：艾叶20份、红花4份、黄柏5份、苦参片4份、臭梧桐4份、白鲜皮1份、黄精5份、当归8份、豨莶草4份、律草15份、茶叶5份、花椒3份、食盐5份。
临床案例：王××，男，35岁，有较为严重的手足癣，还有一定程度的脚汗和脚臭，2013年12月17号开始使用本实施例1制得的足部护理洗液，以1：10到1：30的比例兑入热水，每天两次，每次浸泡30分钟，连续使用两周后，手足癣基本痊愈，足部皮肤变得嫩滑平整，脚臭得到控制，脚汗情况也有好转。
实施例2：一种足部浸泡用中药护理液，它是由以下重量份的原料制成：艾叶25份、红花5份、黄柏8份、苦参片5份、臭梧桐5份、白鲜皮2份、黄精8份、当归10份、豨莶草5份、律草20份、茶叶8份、花椒5份、食盐10份。
临床案例：李×，女，42岁，有长期的手足皲裂，还有一定程度的脚汗和轻微脚臭，2013年11月中旬开始使用本实施例2制得的足部护理洗液，以1：10到1：30的比例兑入热水，每天两次，每次浸泡30分钟，连续使用两周后，手足皲裂痊愈，足部长出新生皮肤，足部其他部位也嫩滑平整，脚汗和脚臭情况消失。
实施例3：优选的，一种足部浸泡用中药护理液，它是由以下重量份的原料制成：艾叶30份、红花6份、黄柏10份、苦参片6份、臭梧桐6份、白鲜皮3份、黄精10份、当归15份、豨莶草6份、律草25份、茶叶10份、花椒6份、食盐15份。
临床案例：胡××，男，17岁，由于经常踢球，有手足癣及脚臭、脚汗，还有一定程度的脚汗和轻微脚臭，2013年12月2日开始使用本实施例3制得的足部护理洗液，以1：10到1：30的比例兑入热水，每天一次，每次浸泡30分钟，连续使用两周后，手足癣基本痊愈，足部不再发痒、脱皮，脚汗和脚臭情况也基本消失。
采用实施例3的洗液治疗脚部皮肤病的临床疗效观察试验统计：本试验仅试验洗液对手足癣、脚汗脚臭和手足皲裂三种病例的疗效情况，共选取患者157人，其中有些患者同时有手足癣、脚汗脚臭、手足皲裂三者中的多种，本试验中仅取每位患者其中的一方面进行观测。
治疗方法为每天使用两次，每次取100ML兑入1L热水，将患者足部浸泡其中，每次浸泡20分钟，一周为一疗程。
治愈为彻底治愈该皮肤病，有效指的是临床体症有明显改善，无效指的是临床体症没有变化，观察结果见表1。
表1：
经过对157例脚部皮肤病患者的观察结果表明，本发明药物对于手足癣、脚汗、脚臭、手足皲裂均有显著的疗效，临床观察未发现不良反应，证明本发明药物组合物是一种安全有效的足部浸泡用中药护理液。
另外，还可以在原料配方中加入肉桂3-6份，吴茱萸2-5份，生姜8-10份，可以达到治疗风冷头痛及过敏性鼻炎的作用，同时可以消除疲劳、改善睡眠，增加了洗液的保健效果。
在原料配方中可以选择性加入连翘、金银花、板蓝根或菊花6-10份，可以达到清热去火解毒的功效，中和冬天咽干、嗓子痛、喉咙痛等上火症状，以及泡脚过程中的热气，达到取长补短的目的。
一种足部浸泡用中药护理液的制备方法，包括以下步骤：
(1)将各组分原料分别进行筛选去除杂质，按所述配比称取，备用；
(2)将黄柏、苦参片、臭梧桐、白鲜皮、黄精、当归、花椒粉碎至50-120目，将原料压扁轧碎处理，再加入15-20倍分量的水，水中可以加入白醋，将其PH值调至4或5，浸泡12-15小时；
(3)往步骤2中的药和水中加入艾叶、红花、豨莶草、律草和茶叶，一同倒入非铁锅中烧开，用小火煎熬，当药液熬至接近一半时，用大火煎熬，当药液熬至接近1/3时，转为文火，直至药液熬至接近1/4时慢慢停火，此步骤中需不时的搅拌药物，避免药物沉积烧焦；
(4)往药液中加入食盐，搅拌溶解后将药液滤出，榨取药渣中的药液，将药液合并，装入容器中密封即得成品。
成品以50-500Ml的规格包装，保存于阴凉、干燥、通风的场所，为了延长保质期，可以适当加入添加剂。适用人群：女性在月经期间不宜使用，孕妇及7岁以下的儿童也不宜使用。
本品为外用产品，泡脚时，将足部浸泡用中药护理液倒入足浴盆的热水中搅拌均匀即可泡脚，水量以漫过脚踝即可，趁热泡脚，以10-30分钟为限，中药通过水温打开了脚部毛孔，使中药的有效成分快速通过毛孔进入足部，从而达到养生保健及治疗的作用。可以去除老脚皮、老茧，治疗手足皲裂、手足癣、灰指甲等疾病，同时又具有活血、化瘀、通经的效果，使脚更加光滑细腻。
手足皲裂及手足癣，都是顽固难治的常见病，采用药物治疗往往效果不是非常明显，并且容易污染衣物，带患者带来身心上的痛苦，通过泡脚的方式用中药方式祛除预防，卫生省事，更加方便。
最后说明的是，以上实施例仅用以说明本发明的技术方案而非对其进行限制，尽管参照较佳实施例对本发明进行了详细说明，但本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本技术方案的宗旨和范围，其均应涵盖在本发明的权利要求范围内。
Claims (4)
1.一种抑制肿瘤细胞再生长的中药配方，其特征在于，它是由以下重量百分比份的原料制成：灵芝10％-15％、红豆杉30％-35％、蟾蜍20％-30％、冬虫夏草5％-10％、西洋参8％-15％、全蝎20％-25％、黄芪15％-20％、半枝莲5％-8％、百花蛇舌草5％-15％。
2.根据权利要求1所述的一种抑制肿瘤细胞再生长的中药配方，其特征在于，它是由以下重量份的原料制成：灵芝10％-12％、红豆杉30％-33％、蟾蜍25％-28％、冬虫夏草6％-8％、西洋参10％-12％、全蝎22％-23％、黄芪16％-18％、半枝莲6％-8％、百花蛇舌草10％-15％。
3.根据上述权利要求所述的一种抑制肿瘤细胞再生长的中药配方的制备方法，其特征在于，包括以下步骤：
(1)将各组分原料分别进行筛选去除杂质，按所述配比称取，备用；
(2)将灵芝、红豆杉、冬虫夏草、西洋参、黄芪、半枝莲、百花蛇舌草混合，再加入10-15倍分量的矿泉水，浸泡5小时；
(3)将步骤2中混合物和水中加入全蝎、蟾蜍，放在石锅中煎熬3-5小时，煎熬的过程中不断的搅拌，待水量剩余一半时，重新加入水，大火煎熬1小时，取30％药液；再次重新加入水，继续大火煎熬3-5小时，取60％药液；
(4)将步骤3中剩余的药渣药液继续采用小火煎熬，待药液浓厚成粘稠状，停止加热，分离药渣和药液；
(5)将步骤4中的药渣，碾碎，备用；
(6)将步骤4和步骤3中所得的药液按照3:2:1的比例，调兑，即可得成品药液。
4.根据权利要求3所述的一种抑制肿瘤细胞再生长的中药配方的制备方法，其特征在于，步骤5和步骤6中所得药渣和药液需同时使用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511022537.9A CN105456428A (zh) | 2015-12-30 | 2015-12-30 | 一种抑制肿瘤细胞再生长的中药配方及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511022537.9A CN105456428A (zh) | 2015-12-30 | 2015-12-30 | 一种抑制肿瘤细胞再生长的中药配方及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105456428A true CN105456428A (zh) | 2016-04-06 |
Family
ID=55594885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511022537.9A Withdrawn CN105456428A (zh) | 2015-12-30 | 2015-12-30 | 一种抑制肿瘤细胞再生长的中药配方及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105456428A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075141A (zh) * | 2016-07-26 | 2016-11-09 | 贵州医科大学 | 一种抗肿瘤中药及其制备方法 |
| CN106177790A (zh) * | 2016-08-29 | 2016-12-07 | 王建斌 | 一种治疗肿瘤的胶囊及其制备方法 |
| CN106421154A (zh) * | 2016-11-29 | 2017-02-22 | 丁明 | 一种具有修复细胞、抗衰老、抗癌功能的沉香中药组合物、中药制剂及其制备方法 |
-
2015
- 2015-12-30 CN CN201511022537.9A patent/CN105456428A/zh not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075141A (zh) * | 2016-07-26 | 2016-11-09 | 贵州医科大学 | 一种抗肿瘤中药及其制备方法 |
| CN106177790A (zh) * | 2016-08-29 | 2016-12-07 | 王建斌 | 一种治疗肿瘤的胶囊及其制备方法 |
| CN106421154A (zh) * | 2016-11-29 | 2017-02-22 | 丁明 | 一种具有修复细胞、抗衰老、抗癌功能的沉香中药组合物、中药制剂及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690783B (zh) | 用于治疗糖尿病的中药制剂及其制备方法 | |
| CN102845745A (zh) | 一种铁皮石斛保健品 | |
| CN101982082B (zh) | 一种养心草复合保健茶 | |
| CN105147847A (zh) | 一种补气养血药物组合物 | |
| CN104208245B (zh) | 手足癣中药药浴及制备方法 | |
| CN102210820A (zh) | 一种治疗白血病的中药组合物 | |
| CN111375010A (zh) | 一种具有扶正固本，补肝益肾，增强免疫功效的中药组合物 | |
| CN104825914A (zh) | 一种辅助治疗乳腺癌症的中药制剂 | |
| CN100462101C (zh) | 治疗再生障碍性贫血的药物 | |
| CN105456428A (zh) | 一种抑制肿瘤细胞再生长的中药配方及其制备方法 | |
| CN1109554C (zh) | 一种治疗过敏性紫癜病的药 | |
| CN105687788A (zh) | 一种软化血管的药物组合物及其应用 | |
| CN102133167A (zh) | 祛斑中药面膜及其制备工艺 | |
| CN104758845A (zh) | 一种治疗肩关节周围炎的外用中药膏 | |
| CN104435545B (zh) | 一种治疗苯中毒致白细胞减少症的中药制剂 | |
| CN104840902A (zh) | 一种治疗卵巢肿瘤的中药制剂 | |
| CN1245197C (zh) | 治疗冠心病、病毒性心肌炎的中药制剂 | |
| CN103055172A (zh) | 一种治疗白癜风的中药组合 | |
| CN115531488B (zh) | 一种疏肝健脾、用于乳腺癌术后辅助治疗的组合物及其制备方法 | |
| CN111388604B (zh) | 一种治疗偏头痛的中药组合物及其制备方法 | |
| CN104784547A (zh) | 对放疗具有增效作用的中药组合物及制备方法 | |
| CN106074904B (zh) | 一种治疗放射性口腔黏膜炎的药物组合物及其制备方法 | |
| CN105031389A (zh) | 一种配合放疗法抑制恶性肿瘤繁殖的中药片剂及制法 | |
| CN104474330A (zh) | 一种治疗面部色斑的药物组合物 | |
| CN110368437A (zh) | 一种清除过敏性紫癜的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160406 |